Navigation Links
AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2011 Financial Results
Date:3/20/2012

REDWOOD CITY, Calif., March 20, 2012 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the fourth quarter and year ended December 31, 2011.

Net loss for the fourth quarter of 2011 was $6.4 million, or $0.33 per share, compared with a net loss of $3.5 million, or $5.23 per share, for the fourth quarter of 2010.  Common shares used in calculating basic and diluted earnings per share were 19,568,000 for the fourth quarter of 2011 compared to 674,000 common shares for the fourth quarter of 2010.

During the fourth quarter of 2011, AcelRx recognized revenue of $624,000 resulting from reimbursement for work completed under a research grant from the US Army Medical Research and Material Command, or USAMRMC, for development of its ARX-04 product candidate, a Sufentanil NanoTab® for the treatment of moderate-to-severe acute pain.  

Research and development expenses for the quarter ended December 31, 2011 totaled $4.7 million, compared with $1.9 million for the quarter ended December 31, 2010.  The increase was primarily due to development expenses for ARX-01, the Sufentanil NanoTab PCA System, AcelRx's lead product candidate for the treatment of post-operative pain, as AcelRx prepared for the initiation of Phase 3 clinical trials which began in early March 2012.  

General and administrative expenses were $1.7 million for the quarter ended December 31, 2011, compared with $1.0 million for the quarter ended December 31, 2010. The increase resulted primarily from expenses associated with AcelRx's operation as a public company.

For the year ended December 31, 2011, AcelRx reported a net loss of $20.1 million, or $1.16 per
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
2. AcelRx Initiates a Phase 2 Study to Evaluate Functionality of Its ARX-01 Sufentanil NanoTab PCA System
3. AcelRx Announces Positive Phase 2 Results from a Study of ARX-01 Sufentanil NanoTabs in Treating Post-Operative Pain
4. AcelRx Programs to be Featured in Oral Presentations at the American Society of Anesthesiologists 2009 Annual Meeting
5. AcelRx to Present at the Lazard 6th Annual Healthcare Conference
6. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
7. AcelRx Pharmaceuticals Files Registration Statement for Proposed Initial Public Offering
8. AcelRx Pharmaceuticals Announces Pricing of Its Initial Public Offering
9. AcelRx Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
10. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2010 Financial Results
11. AcelRx Pharmaceuticals to Present at the JMP Securities Research Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014 NxStage Medical, Inc. (NASDAQ: ... innovative dialysis products, announced today that the U.S. ... System One™ to perform hemodialysis overnight while the ... nocturnal hemodialysis. NxStage,s® System One is the first ... for this indication. Home nocturnal ...
(Date:12/22/2014)... a privately-held medical products and technologies company, today announced ... Officer of the company, effective December 22, 2014. ... Board of Directors of ConvaTec thanks Mr. Berger for ... years," said Magnus Lundberg , the Chairman of ... company is well positioned for the future."  The company ...
(Date:12/22/2014)... Calif. , Dec, 22, 2014  Eiger ... Phase 2a study of lonafarnib in patients with ... was conducted at the National Institutes of Health ... .  The double-blinded, randomized, placebo-controlled, dose ascending ... twice daily and 200 mg twice daily for ...
Breaking Medicine Technology:NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
(Date:12/22/2014)... new vaccine created to fight an illness similar to ... and even humans from similar brain infections, researchers report. ... becoming infected by the incurable brain disorder known as ... Dec. 21 online edition of the journal Vaccine ... particles known as prions that go rogue. Prion ...
(Date:12/22/2014)... December 22, 2014 Super Saturday, the ... this year as the busiest day in the 2014 ... The Grass Station had a steady pre-Christmas stream of ... this past Saturday. , “I definitely intend to take ... a Denver resident who was enjoying The Grass Station’s ...
(Date:12/22/2014)... Naples, Florida (PRWEB) December 22, 2014 ... this holiday season, the gift of health and vitality. ... is offering its three top-selling anti-aging formulas in special ... with free rush delivery. , Each bottle contains ... digestion, areas that don't work as well as we ...
(Date:12/22/2014)... CA (PRWEB) December 22, 2014 ... now offering consultations for sleep apnea. Drowsy drivers are ... than drivers who are well-rested, and some experts believe ... the roads as intoxicated drivers. Unfortunately, millions of Americans ... the American Academy of Sleep Medicine, about 18 million ...
(Date:12/22/2014)... Farmers Branch, TX (PRWEB) December 22, 2014 ... the revolutionary work glove with many useful features. Customers ... savings and can have the new gloves delivered to ... manufactures work gear and hand tools that incorporate heavy ... Pro Utility Magnetic Glove allows workers to store metal ...
Breaking Medicine News(10 mins):Health News:Vaccine for Deer Against 'Mad Cow'-Like Illness Shows Promise 2Health News:Customers at Colorado’s Grass Station Say They’re Enjoying the Experience of Legally Purchasing Marijuana this Year to Give as Christmas Presents to Friends and Family 2Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:MagnoGrip Pro Utility Magnetic Gloves on Sale at TheHardwareCity.com 2
... took substances without approval , , MONDAY, March 3 ... frequently abused prescription drugs increases the risk of drug ... Sean Esteban McCabe asked 3,639 college students, average age ... four classes of prescription drugs -- opioids, stimulants, sleeping ...
... a clear association, but no such link for depression , , ... can help bring on a stroke may have merit, British ... different groups according to how severe their stress is, someone ... a 40 percent increased risk of stroke than someone in ...
... YORK, March 3 With New York physicians,facing a ... to a projected premium increase, an expected one thousand ... the Egg, Empire State,Plaza, on Tuesday, March 4th where ... and then march on the Capitol steps by 12:30 ...
... March 3 Emageon Inc.,(Nasdaq: EMAG ), ... hospitals, healthcare networks and imaging facilities announced,today that ... at the,Raymond James 29th Annual Institutional Investors Conference ... Cypress, Orlando, Florida. Emageon will,present on Wednesday, March ...
... Care Problems ... Media Availability Today 5,000 Nurses ... March 3 In an atmosphere that nurses,describe as attempted "intimidation" ... tomorrow to authorize,their bargaining teams to strike the hospital chain for ...
... Protecting State,s,Elderly from Price Gouging, Ensure Safety ... California,seniors who feel price-gouged by providers ... advocates and elected leaders to fight back ... problems with emergency,preparedness. Legislation introduced by Assembly ...
Cached Medicine News:Health News:Non-Medical Use of Prescriptions Linked to Drug Abuse Risk 2Health News:Stress Can Help Trigger Stroke 2Health News:Attention New York: Please Don't Get Sick on March 4th, Your Doctor Will be in Albany for Malpractice Insurance Reform 2Health News:In Face of Hostile Bargaining and Intimidation by Management, Mills-Peninsula to Vote to Authorize Strike 2Health News:In Face of Hostile Bargaining and Intimidation by Management, Mills-Peninsula to Vote to Authorize Strike 3Health News:'Atria Bills' Get Support From Assisted Living Residents, Family Members, Senior Groups 2
Latex agglutination slide test for the qualitative and quantitative detection of rubella virus antibody in serum....
Hemagglutination slide test for the qualitative and quantitative detection of Rheumatoid Factor in serum or synovial fluid....
A Color-Enhanced Slide Agglutination Test for the Rapid Qualitative and Semi-Quantitative Detection of Rheumatoid Factor in Serum....
Hemagglutination slide test for the qualitative and quantitative detection of infectious mononucleosis heterophile antibodies in serum or plasma....
Medicine Products: